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The clinical and bacteriological efficacy and safety of the antibiotics ceftazidime or
imipenem/cilastatin in seriously ill patients with nosocomial infections were
compared in a prospective, open, evaluator-blind, multicentre comparative trial. The
study was performed in 26 European centres, the majority being intensive care units.
Subjects were randomized to receive either ceftazidime 2 g bid or imipenem cilas-
tatin 0-5 g qid given for at least five days after stratification for pneumonia,
septicaemia or urinary tract infection (UTI). Three hundred and ninety-three
patients with serious nosocomial infections (254 with pneumonia; 91 with septi-
caemia and 48 UTI were treated between February 1988 and January 1990 and their
clinical and bacteriological response to antibiotic treatment assessed. There were no
significant differences between ceftazidime and imipenem/cilastatin in clinical effi-
cacy. The failure rates in evaluable patients were 22 and 26% in pneumonia, 23 and
19% in septicaemia and 0 and 5% respectively in those with UTI. Overall there was
no significant difference between the two antibiotics for bacteriological response in
the three infection strata. However, in patients with pneumonia ceftazidime was
significantly more effective than imipenem/cilastatin in clearing patients of
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Pseudomonas spp.: 3/17 and 11/19 patients respectively had persistent growth of
Pseudomonas spp. post-treatment (P = 0004), and in one ceftazidime failure resist-
ance emerged compared to six imipenem/cilastatin failures in which resistance
emerged. Few drug-related adverse events were recorded in either treatment group.
Monotherapy with either ceftazidime (2 g bid) or imipenem/cilastatin (0-5 g qid) is
safe and effective and could be considered as an alternative to combination therapy
for the treatment of serious hospital-acquired infections.
Introduction
Hospital-acquired infections are common and may be life-threatening. The most
serious are pneumonia and septicaemia, which may originate from infectious foci in the
lungs, the urinary tract or other sites. Nosocomial pneumonia presents a particular
problem, especially in patients requiring assisted ventilation. In such patients colon-
ization of the oropharynx with multiresistant hospital pathogens can lead, in the
absence of mechanical or local defences, to a very high incidence of nosocomial
pneumonia, as shown in several recent studies (Stoutenbeek et al., 1987; Ledingham et
al., 1988). Aerobic Gram-positive or Gram-negative bacterial pathogens are the most
common causative agents. Anaerobes may be important in patients who have
developed pneumonia after aspiration of gastric contents and in those with lung
abscesses or empyema (Carpenter, 1990).
The treatment of nosocomial infections should cover the most common aerobic
bacterial species, including Staphylococcus aureus and Pseudomonas aeruginosa.
Previously this could only be achieved with combination antibiotic therapy, usually an
aminoglyoside with a broad spectrum /Mactam. However, a clear drawback to the use
of aminoglycosides in patients with pneumonia is the need for high doses in order to
achieve an optimal therapeutic outcome (Moore, Smith & Lietman, 1984). This may be
due to the pH of bronchial secretions, which is considerably below the optimum pH for
aminoglycoside antibacterial activity (Laforce, 1989).
Recently the development of potent parenteral antibiotics with broad antibacterial
activity has offered the potential use of monotherapy for the treatment of serious
hospital-acquired infection (Gardner, 1983; Laforce, 1989). Such monotherapy would
reduce the treatment costs, and possibly also the risk of adverse reactions from
combinations of antibiotics.
This study was undertaken to compare the efficacy of two broad-spectrum anti-
biotics, ceftazidime and imipenem/cilastatin in the empirical treatment of serious
infections developing in patients hospitalized for at least 48 h. Ceftazidime and
imipenem/cilastatin both cover a wide range of nosocomial pathogens, and have been
extensively used as monotherapy in serious infections, including the treatment of sepsis
in immunodeficient patients (Clissold, Todd & Campoli-Richards, 1987; Sanders, Powe
& Moore, 1991). The notable feature of ceftazidime is its activity against P. aeruginosa,
while imipenem/cilastatin has greater activity than third generation cephalosporins
against staphylococci and anaerobes.
Methods
The study was undertaken in 26 European centres between February 1988 and January
1990. The protocol was approved by the Ethics Committee in each participating centre,
and informed consent, either verbal or written, was requested from the patient or a
relative before entering the trial.
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Trial design
This was a prospective, open, evaluator-blind, multicentre comparative trial. Patients
were randomized by the use of sealed, numbered envelopes. Allocation to treatment
was in blocks of six, and within each bloc, three patients received each treatment.
Stratification was made for pneumonia, septicaemia, or UTI.
Sample size
Sample size was determined based on the assumption that the expected clinical
response rate (cure and improvement) for ceftazidime and imipenem/cilastatin was
approximately 85% at the post-treatment visit. Thus approximately 160 clinically
evaluable patients were required in each treatment group to detect a difference in
response rate of 10% with 80% power using a 5% level of significance.
Patients
Hospitalized adult patients ( > 16 years) who developed clinical signs of pneumonia,
septicaemia or severe UTI 48 h or more after hospital admission were eligible. Patients
who had received previous antibiotic treatment were included only if they had failed to
improve or the relevant pathogen had not been eliminated. As a measure of severity of
illness, APACHE II scores were calculated in most patients at entry (Knaus et al.,
1985). Clinical pneumonia was defined as a new or progressive pulmonary infiltrate on
chest X-ray without a known non-infectious cause but with negative or unobtainable
bacteriological investigation. In patients with bacteriologically verified pneumonia,
organisms considered by the monitoring committee to be clinically relevant must have
been isolated from purulent sputum, bronchial secretion, bronchial washing, lung tissue
or blood culture. Clinical septicaemia was defined as clinical deterioration and rigors in
association with unstable haemodynamic parameters and/or coagulopathy consistent
with sepsis in the absence of positive blood cultures. Patients with a bacteriologically
documented septicaemia had one or more positive blood cultures, although blood
cultures which grew coagulase-negative staphylococci or diphtheroids in only one
bottle were considered to be contaminated. Severe UTI included acute pyelonephritis
(fever associated with loin pain or tenderness and associated with significant bac-
teriuria, namely, > 107 cfu/L urine) or complicated UTI (significant bacteriuria in a
systemically unwell patient with a temperature > 38-5°C and structural or functional
abnormalities of the urinary tract, known to predispose to, or permit persistence of,
infection). Exclusion criteria for study entry were hypersensitivity to cephalosporins,
carbapenems or penicillins, neutropenia ( < 10 x 10'L), likelihood of death within
24 h, isolation before therapy of pathogens known or suspected to be resistant to either
of the study drugs, therapy with ceftazidime or imipenem/cilastatin within the previous
four weeks, and previous entry into the study.
Antibiotic treatment
Ceftazidime (Glaxo) was administered in 2 g doses every 12 h as bolus intravenous
injections over 5-10 min or as intermittent infusions over 20-30 min.
Imipenem/cilastatin (Merck Sharp & Dohme) was given in doses of 500 mg every 6 h
as intermittent infusions over 30 min. With both drugs, doses were reduced in patients
with compromised renal function in accordance with the recommendations of the
manufacturers.
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Assessment of response
Clinical response was assessed as cure (clinical symptoms and signs subsided with
complete resolution of active infection during the treatment period) or failure (change
of antibiotic therapy because of initial isolation of a resistant organism, addition of a
new antibacterial agents at any time during treatment, because of clinical deterioration
or superinfection at the primary site of infection, and death due to infection). In
addition, for pneumonia and severe UTI a category of improvement (clinical signs and
symptoms subsided but with incomplete resolution of active infection during treatment)
was allowed. Clinical relapse was defined as recurrence of clinical signs and symptoms
of the initial infection during the follow-up period, after initial cure or improvement.
Bacteriological response was assessed 24—48 h after the end of treatment in patients
with pneumonia or septicaemia and five to nine days after treatement in those with
UTI. It was classified as clearance (absence of the original pathogen(s) in a post-
treatment sample or unavailability of such sample in a clinically cured patient), partial
clearance (at least one of multiple pathogens eliminated in the post-treatment sample),
or failure (continued isolation of the original pathogen(s) at the end of treatment). In
patients with UTI repeat urine samples were obtained four to six weeks post-treatment.
Isolation of a new organism at the initial site of infection during treatment, or within
two days after treatment, was classified as colonization if no further treatment was
required and superinfection if treatment was started.
Susceptibility testing
All relevant organisms isolated at each of the participating centres were tested for
susceptibility to ceftazidime and imipenem/cilastatin by a disc diffusion method (either
Kirby-Bauer (70% of centres) or Stokes (30% of centres)). Susceptibility testing was
carried out using imipenem/cilastatin (10 ng) and ceftazidime (30 /ig) discs on DST,
Iso-Sensitest or Mueller-Hinton agars (Oxoid, BBL). Isolates were categorized as
susceptible, intermediate or resistant to ceftazidime and imipenem/cilastatin according
to the criteria laid down by the National Committee for Clinical Laboratory Standards
(NCCLS) in 1987. In addition, the isolates were also sent to a central laboratory for
confirmation of identity and minimum inhibitory concentration (MIC) determination.
MICs were determined on solid medium (Iso-Sensitest, Oxoid), and interpreted
according to the NCCLS (1987) guidelines: ceftazidime-susceptible ( ^ 8 mg/L) ceftazi-
dime-intermediate (16 mg/L), ceftazidime-resistant ( ^ 32 mg/L), imipenem/cilastatin-
susceptible ( < 4 mg/L), imipenem/cilastatin-intermediate (8 mg/L), imipenem/cilas-
tatin-resistant ( ^ 16 mg/L).
Adverse event monitoring
The investigators were asked to register all unexpected clinical events during or within
14 days after treatment.
Patient evaluation
Case record forms were filled out by the investigators, screened for accuracy by a
monitor and evaluated by one of the members of the monitoring committee (S.R.N.),
who was blinded to treatment allocation. The blinded evaluator assessed the clinical
and bacteriological responses, and reviewed adverse events. Cases in which the assess-
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ments of the investigators were changed were discussed by all members of the
monitoring committee (S.R.N., R .G.F . and M.G.).
Statistical analysis
The treatment groups were compared within each stratum, with respect to demographic
and other baseline variables. The distribution of clinical response at the post-treatment
assessments was analysed using log-linear models to take account of stratification,
which included the terms for the response categories, treatments allocated and infec-
tion. Comparisons of cure and improvement rates were carried out similarly. The odds
ratio for clinical response, which illustrates a measure of the odds in favour of being
cured or improved using ceftazidime, as opposed to using imipenem/cilastatin was
calculated. In addition, each infection stratum was examined separately for the cure
and improvement rates using the chi-squared test. Relapse rates in those initially cured
or improved were compared within each stratum using continuity corrected chi-squared
test. In the case of small numbers of relapse rates (less than five) occurring for each of
the treatments within each stratum Fisher's Exact test was applied. Bacteriological
clearance rates were compared between treatment groups for all three strata, using chi-
squared test and in some cases Fisher's Exact test. Log-linear models were used to
compare the treatment groups for the septicaemia and pneumonia strata. An odds ratio
for the bacteriological response in pseudomonal and staphylococcal pneumonia was
then calculated. Superinfection rates were compared between treatment groups using
chi-squared test. The treatment groups were compared, within stratum, with respect to
incidence of adverse events using Fisher's Exact Test.
Results
Patient population
Three hundred and ninety-three patients were recruited, of which 196 received ceftazi-
dime and 197 imipenem/cilastatin. The two groups were well balanced with respect to
age, sex, type of infection, duration of treatment, prognosis of underlying disease, and
numbers in intensive care and on assisted ventilation (Table I). The APACHE II scores
assessed in 344 patients clearly demonstrated that patients with pneumonia or septi-
caemia were more seriously ill at the start of treatment than patients with UTI.
Forty-six per cent of patients in each arm had received previous antibiotic treatment.
Forty-two patients on ceftazidime and 35 on imipenem/cilastatin were considered to
be clinically unevaluable. Reasons were failure to meet protocol definition of nosoco-
mial infection (32 on ceftazidime and 25 on imipenem/cilastatin), concurrent treatment
with other antimicrobials (eight patients on ceftazidime, three on imipenem/cilastatin)
and death due to underlying disease (two patients on ceftazidime, seven on imipenem/
cilastatin). Patients were omitted from the bacteriologically efficacy analysis if either
specimens failed to give a pathogen before the start of treatment or there were no valid
pre- or post-treatment cultures.
Clinical response
There were no significant differences between the distribution of clinical responses of
the two treatments for all patients (P = 0-65) and for evaluable patients only {P =
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Table I. Patient characteristics
Characteristic ceftazidime
Treatment
imipenem/cilastin
Number of patients entered
pneumonia
septicaemia
renal/urinary infection
Sex (male/female)
Mean age (years; range)
Prognosis of underlying disease
non-fatal
ultimately fatal
rapidly fatal
unknown
Number of patients in intensive care units
(% of entered)
Number of patients on assisted ventilation
(% of entered)
APACHE II score at entry (mean±SEM)
all assessed (N = 344)
pneumonia (N = 237)
septicaemia (N = 82)
urinary tract infection (N = 25)
Mean duration of treatment (days; SD)
196
125
47
24
122/74
58 (18-92)
100(51%)
82 (42%)
12 (6%)
2
142 (72%)
97 (49%)
13-8±0-5
13-6±0-6
15-7±1-1
9-4 ±1-5
8-8 ±3-6
197
129
44
24
129/68
58 (16-90)
97 (49%)
78 (40%)
21 (11%)
1
143 (73%)
100(51%)
14 1 ±0 5
14-4 ±0-5
141 ±0-9
ll-5±2-2
9-7 ±4-0
0-62). The clinical cure plus improvement rates were also not found to be significantly
different between treatment groups, both including and excluding unevaluable patients
(Table II).
The odds in favour of an infection being cured or improved by ceftazidime as
opposed to imipenem/cilastatin was found not to be significant, as illustrated by the
95% confidence interval of the odds ratio covering 1 (06, 1-4).
When the individual chi-squared tests (both including and excluding unevaluable
patients) for each infection stratum were examined, again there were no significant
differences between treatment groups.
The percentage of clinically cured or improved patients who experienced clinical
relapse during the follow-up period was not significantly different between the two
groups for any of the three strata (for pneumonia: ceftazidime 13%, imipenem/
Table II. Clinical response to treatment
Response
Pneumonia
CAZ IMI
(n = 125) (n = 129)
Septicaemia
CAZ IMI
(/» = 47) in = 44)
UTI
CAZ IMI
(n = 24) (n = 24)
Cured
Improved
Failure
Unevaluable
45%
18%
18%
19%
49%
14%
22%
15%
53%
0%
19%
28%
59%
0%
14%
27%
75%
8%
0%
16%
75%
8%
4%
13%
CAZ, Ceftazidime; IMI, imipenem/cilastatin.
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Table m . Pre-treatment pathogens
Type of infection and treatment
pneumonia septicaemia UTI
CAZ IMI CAZ IMI CAZ IMI
Number of padents 57 62 30 33 24 24
Number of isolates 76 82 35 35 27 30
Pathogens:
S. aureus 18 16 3 4 0 0
Staphylococcus spp. 0 0 3 1 1 3
Streptococcus spp. 4 3 2 2 1 4
Haemophilia spp. 8 8 0 0 0 0
E. coli 9 12 6 7 15 6
Klebsiella spp. 7 6 7 5 4 3
Enterobacter spp. 2 4 1 3 0 3
Proteus spp. 4 4 1 2 2 2
Acinetobacter spp. 4 3 1 1 0 0
Serratia spp. 2 2 2 0 1 1
Citrobacter spp. 1 2 0 0 0 1
P. aeruginosa 16 14 8 6 2 6
Psudomonas spp. 1 5 0 2 1 0
Other Gram-negatives 0 3 1 2 0 1
CAZ, Ceflazidime; IMI, imipenem/cilastatin.
cilastatin 17%, for septicaemia: ceftazidime 8%, imipenem/cilastatin 8% and for UTI:
ceftazidime 25%, imipenem/cilastatin 40%).
Finally, no significant difference was found in the distribution of superinfection rates
between the two treatment groups (ceftazidime 9%, imipenem/cilastatin 5%). The
superinfecting organisms were S. aureus, coagulase-negative staphylococci,
Enterobacter spp., Klebsiella pneumoniae, P. aeruginosa, Candida spp. and Aspergillus
spp. in ceftazidime treated patients; and coagulase-negative staphylococci,
Pseudomonas spp., Enterobacter spp., K. pneumoniae, and Candida spp. in those
receiving imipenem/cilastatin. In both groups Enterococcus faecalis was the main
superinfecting organism in the urinary treat.
Bacteriological response
Two hundred and eight-five organisms, considered to be pathogens by the monitoring
committee, were isolated pre-treatment from 230 patients (Table HI). Gram-negative
organisms predominated, the most common being Escherichia coli (19% of all isolates)
and P. aeruginosa (18%). Among Gram-positive species, S. aureus (14% of all isolates)
was the most common. A majority of the patients had single organisms. Overall, there
was no significant difference between the two antibiotics in bacteriological response in
the individual infection categories. Subgroup analysis in patients with pseudomonal
pneumonia (Table IV) showed that significantly more patients failed to respond
microbiologically (P = 0-004), though not clinically, to imipenem/cilastatin than to
ceftazidime. Bacteriological clearance occurred with imipenem/cilastatin in only 54%
of the clinically cured or improved pseudomonal pneumonias, and in none of the
clinical failures. The odds in favour of a patient being cleared of pseudomonal
pneumonia was eight times greater when using ceftazidime as opposed to using
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Table IV. Outcome in evaluable patients with pseudomonal
pneumonia
Clinical
response
Cured/improved
Failed
Bacteriological
response
Cleared
Persistence
Cleared
Persistence
Unassessable
Percentage
CAZ
(« = 13)
85%
15%
(« = 4)
75%
25%
0%
of patients
IMI
( » = 13)
54%
46%
(«±6)
0%
83%
17%
CAZ, Ceftazidime, IMI, imipenem/cilastatin.
imipenem/cilastatin (95% confidence interval 1-7-38). Furthermore, in six of the
11 imipenem/cilastatin patients in whom the organism persisted, resistance to the study
drug developed during treatment; this was found in only one patient on ceftazidime.
In patients with pneumonia caused by S. aureus, 12 of 18 patients in the ceftazidime
group and 12 of 16 in the imipenem/cilastatin group were cured or improved clinically.
Persistence of staphylococci was seen in five ceftazidime patients, of whom three were
clinical failures. In the imipenem/cilastatin group, only one strain persisted and that
patient also failed clinically. This difference was not statistically significant.
A sample of around 35% of the isolates was sent from the participating study centres
to a central laboratory for both identification and determination of their MICs to
ceftazidime and imipenem. Results obtained by the study centres and the central
laboratory were consistent in about 90% of cases with respect to the identity of isolates.
By conversion of the MICs (from the central laboratory) to categories of susceptible,
moderate and resistant (from the study centres), using breakpoint concentrations
specified in the NCCLS guidelines, susceptibility results were shown to be consistent in
over 70% of cases. These results indicate a comparable expertise in identification and
susceptibility testing throughout the participating centres.
Adverse events
Overall 42 (21%) patients in the ceftazidime treatment group and 55 (28%) in the
imipenem/cilastatin treatment group experienced one or more adverse events. The
Table V. Adverse events considered drug-related
Adverse effect
Rash
Drug fever
Phlebitis
Diarrhoea
Grand mal seizure
Candida superinfection (oral/genital)
Elevated creatinine
Treatment and
CAZ
(« = 4)
1
1
0
2
0
0
0
number of patients
IMI
(« = 8)
2
0
1
1
I
2
1
CAZ, Ceftazidime; IMI, imipenem/cilajtatin.
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difference in incidence between the two treatment groups was not statistically signifi-
cant. The majority of adverse events were not considered by the investigators to be
drug-related. Only 12 patients (four ceftazidime, eight imipenem/cilastatin) had adverse
events which were considered by the investigators to be possibly, probably or almost
certainly related to antibiotic treatment (Table V). Treatment was discontinued due to
adverse events in three patients; two on ceftazidime, and one on imipenem/cilastatin.
One patient on imipenem/cilastatin experienced a single grand mal seizure on each of
two consecutive days which resolved, with no further recurrence, after a decrease in the
dose.
Thirty-one of the patients receiving ceftazidime died during treatment, or within the
14 day follow-up period. Three of these died during treatment due to bacterial sepsis.
This compares with 20 and four patients respectively on imipenem/cilastatin. All deaths
were considered unrelated to the study drugs.
Discussion
This study demonstrates that ceftazidime and imipenem/cilastatin are both effective as
monotherapy in seriously ill patients with nosocomial infections. There were no
significant differences between ceftazidime and imipenem/cilastatin in clinical efficacy:
the proportion of evaluable patients receiving ceftazidime who were cured or improved
ranged from 74 to 100% depending on the infection, and from 74 to 95% for those
given imipenem/cilastatin. The frequency of isolation of individual pathogens in this
study was similar to other reports in the literature (Horan et al., 1988; Scheld &
Mandell, 1991).
In patients with pneumonia 23% of pathogens isolated were P. aeruginosa or other
Pseudomonas spp. Significantly more of these organisms persisted in patients who were
given imipenem/cilastatin than in those who received ceftazidime, but this was not
always associated with clinical failure. This suggests that in some patients the
P. aeruginosa strains may not have been the causative agents. One possible explanation
for the development of resistance to imipenem/cilastatin seen in around half of the
persistent isolates in this study is that the 0-5 g dose of imipenem/cilastatin study gives
plasma concentrations above the minimum inhibitory concentration for P. aeruginosa
for about 2-5 h. This relatively low dose could have resulted in the development, during
treatment, of imipenem-resistant P. aeruginosa, a phenomenon which has been
reported previously (Acar, 1985; Krilov et al., 1985; Salata et al., 1985). It is of interest
that the principal resistance mechanism in P. aeruginosa to these compounds is
different. With ceftazidime, resistance is generally associated with /Mactamase produc-
tion, which may also promote variable imipenem/cilastatin resistance.
Imipenem/cilastatin resistance, on the other hand, derives from altered permeability via
a protein change (Trias & Nikaido, 1990): the protein D2 which is responsible for
specific transport of imipenem into P. aeruginosa is not present in resistant isolates.
This large trial has emphasized certain points: the APACHE II scoring system
proved reliable in the classification of the seriousness of disease and for stratifying the
degree of risk of subsequent death. It indicated that the patients with UTT were less
seriously ill, but excluding these patients did not alter the overall outcome. With the
fixed sample size chosen the high response rates seen with both treatments in patients
with severe UTI could have reduced substantially the capacity to detect a difference in
outcome in the two more serious conditions of pneumonia or septicaemia. In future
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studies of nosocomial infections, severe UTI should be evaluated in a separate
protocol.
In the patients with pneumonia the protocol definition was adhered to and cases of
purulent tracheobronchitis were excluded from the evaluation of efficacy, although
many authorities recognize that this group of patients (particularly those with
P. aeruginosa in tracheal aspirates) warrant antibiotic treatment. Likewise, cases of
ARDS (19 in all) were excluded from clinical evaluation unless an infectious complica-
tion such as empyema or a superinfection in the blood developed.
Again, in cases of pneumonia in the Intensive Care Unit bacteriological confirmation
is imprecise. The upper airways of patients are commonly colonized with potential
respiratory pathogens, with the result that organisms obtained from tracheal suction or
sputum are not necessarily diagnostic. In this study respiratory specimens came from a
variety of sources, but the pathogens isolated were consistent with a nosocomial
pattern of infection.
In addition, in patients with pneumonia and in whom P. aeruginosa was isolated,
there was a clear correlation between failure to eradicate these organisms and poor
clinical outcome, especially in the imipenem/cilastatin group. Of course, bacteriological
diagnosis can be improved by the use of a fibre-optic bronchoscope with either
broncho-alveolar lavage or the use of the protected specimen brush (Thorpe et al.,
1987; Faling, 1988; Fagon et al., 1988). Quantitative culture will enhance the specificity
of both methods, and it seems appropriate to recommend the use of these techniques
for future studies in this population of patients.
In conclusion, this trial has demonstrated that single agent treatment can given
satisfactory results in severe hospital acquired infections, including pseudomonal
pneumonia, in non-neutropenic patients. The choice of antibiotic in an individual
hospital or unit should be made after the consideration of several factors, including
local sensitivity patterns.
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